CAR-T Cell Therapy vs Gene Therapy — Clinical Trial Comparison
CAR-T Cell Therapy
Engineered T-cells programmed to hunt specific cancer cells
VS
Gene Therapy
Genetic material delivered to cells to treat disease at the DNA level
CAR-T cell therapy and gene therapy are both classified as Advanced Therapy Medicinal Products (ATMPs) — the cutting edge of modern medicine. CAR-T specifically engineers a patient's immune cells to target cancer, while gene therapy encompasses a broader range of approaches that alter genetic material to treat disease. Both represent paradigm shifts from traditional pharmaceuticals, and both have flourishing UK trial landscapes. Understanding their differences helps you find the right trial for your situation.
Key Differences at a Glance
| Feature | CAR-T Cell Therapy | Gene Therapy |
|---|---|---|
| Mechanism | T-cells are collected, genetically modified with a CAR (chimeric antigen receptor), expanded, and infused back to target cancer cells expressing a specific antigen | Genetic material (DNA, RNA, or gene-editing tools) is delivered to cells to correct, replace, silence, or add genes — treating disease at the genetic level |
| Approach | Ex vivo — cells are modified outside the body in a GMP manufacturing facility | Can be ex vivo (cells modified outside body) or in vivo (genes delivered directly to patient via viral vector or nanoparticle) |
| Disease focus | Primarily blood cancers (ALL, DLBCL, MCL, ALL, myeloma); expanding into solid tumours and autoimmune disease | Inherited genetic disorders, haemophilia, sickle cell disease, eye diseases, neurological conditions, and some cancers |
| Gene modification | Adds a single synthetic receptor gene (CAR) to T-cells using lentiviral or retroviral vectors | Can add, replace, silence, or edit genes using viral vectors (AAV, lentivirus), CRISPR/Cas9, or other technologies |
| Manufacturing | Autologous (patient-specific) — each product is unique; takes 2–4 weeks | Can be autologous or allogeneic (off-the-shelf); AAV-based therapies are manufactured in bulk |
| Duration of effect | Potentially long-lasting — CAR-T cells can persist for years; some patients remain in remission 5+ years after single infusion | Varies — AAV gene therapy can provide long-lasting expression (years); some approaches need redosing; genome editing aims for permanent correction |
Clinical Trial Availability
| Trial Aspect | CAR-T Cell Therapy | Gene Therapy |
|---|---|---|
| UK trials actively recruiting | 80–120 studies | 150–250 studies |
| Most common phases | Phase 1–2 (many early-phase); some Phase 3 for approved targets | Phase 1–3 (more advanced for inherited disorders; earlier for novel targets) |
| Top conditions studied | ALL, DLBCL, follicular lymphoma, mantle cell lymphoma, multiple myeloma, ALL (solid tumours emerging) | Haemophilia A/B, sickle cell disease, beta-thalassaemia, retinal dystrophies, SMA, Duchenne MD, Parkinson's, cystic fibrosis |
| Manufacturing location | UK GMP facilities (UCL, GSK, Autolus, Gilead/Kite, NHS Blood and Transplant) | UK and international facilities; AAV manufacturing scaling rapidly |
| Trial availability by centre | Limited to major cancer centres (UCLH, Christie, Birmingham, Oxford, Cambridge, Glasgow) | More distributed — genetic disorder trials at many NHS trusts plus specialist centres |
| Paediatric availability | Yes — paediatric ALL is a major CAR-T indication; dedicated paediatric trials | Yes — many gene therapy trials focus on paediatric genetic disorders (SMA, haemophilia, SCID) |
Exciting Emerging Treatments
CAR-T Cell Therapy Trials
- Allogeneic (off-the-shelf) CAR-T — universal CAR-T from healthy donors using CRISPR to prevent rejection
- Solid tumour CAR-T — novel targets (CLDN18.2, GPC3, HER2, mesothelin) for liver, gastric, and lung cancers
- Dual-target CAR-T — expressing two CARs to prevent antigen escape
- Autoimmune CAR-T — CD19 CAR-T for lupus, MS, and other autoimmune conditions (breakthrough results)
- Armoured CAR-T — engineered to secrete cytokines or checkpoint blockers in the tumour microenvironment
- In vivo CAR-T — delivering CAR genes directly via viral vectors, eliminating ex vivo manufacturing
Gene Therapy Trials
- CRISPR/Cas9 gene editing — precise correction of disease-causing mutations (sickle cell, beta-thalassaemia now approved)
- Base editing — even more precise editing without cutting DNA (cholesterol, leukaemia trials)
- mRNA gene therapy — non-permanent gene delivery using mRNA technology
- AAV gene therapy — expanding from rare diseases to more common conditions (heart failure, Alzheimer's)
- Gene therapy for neurodegeneration — delivering neuroprotective genes in Parkinson's, ALS, Huntington's
- In utero gene therapy — treating genetic disorders before birth (early research phase)
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
CAR-T Trial Criteria
- Confirmed diagnosis of target condition (e.g., relapsed/refractory DLBCL after ≥2 lines)
- Target antigen expression confirmed (CD19, BCMA, etc.)
- Adequate organ function (heart, liver, kidney, lungs) to withstand lymphodepletion and infusion
- ECOG performance status 0–1 (sometimes 0–2)
- No active uncontrolled infection
- Adequate T-cell function and count for apheresis collection
Gene Therapy Trial Criteria
- Confirmed genetic diagnosis (specific mutation identified through genetic testing)
- Disease severity criteria (some trials require early-stage disease, others advanced)
- No pre-existing immunity to the viral vector (AAV antibodies tested for AAV-based therapies)
- Adequate organ function for the specific delivery route
- Age criteria — many paediatric trials; some adult-only for age-of-onset conditions
- No concurrent gene therapy or advanced therapy participation
Frequently Asked Questions
Is CAR-T cell therapy a type of gene therapy?
Technically, yes — CAR-T cell therapy involves genetically modifying T-cells using viral vectors to express a chimeric antigen receptor. In regulatory terms, CAR-T is classified as an Advanced Therapy Medicinal Product (ATMP). However, when people say 'gene therapy,' they usually mean treatments that deliver genes directly to the patient's body cells (in vivo) rather than modifying cells outside the body (ex vivo) as CAR-T does. The distinction matters for trial eligibility and regulatory pathways.
Which has more UK clinical trials — CAR-T or gene therapy?
Gene therapy has more trials overall (200+ UK studies) because it covers a broader range of diseases including inherited disorders, eye diseases, and neurological conditions. CAR-T trials (100+ UK studies) are more concentrated in haematological cancers but are rapidly expanding into solid tumours and autoimmune diseases. Both fields are growing fast.
Can gene therapy be used for cancer?
Yes — gene therapy approaches for cancer include oncolytic viruses (viruses engineered to kill cancer cells), gene-modified T-cells (CAR-T, TCR therapy), gene editing to disrupt immune checkpoints, and tumour suppressor gene replacement. While CAR-T is the most established cancer gene therapy, many other gene therapy approaches are in trials for solid tumours.